Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Tofilon Website

Philip Tofilon, Ph.D.

Selected Publications

1)  Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.
The mTORC1/mTORC2 Inhibitor AZD2014 Enhances the Radiosensitivity of Glioblastoma Stem-like Cells.
Neuro-Oncology. 2013.
In Press. [Journal]
2)  Tandle AT, Shankavaram U, Brown MV, Ho J, Graves C, Lita E, Pfohl J, Mohney R, Tofilon PJ, Camphausen K.
Urinary metabolomic profiling of patients with glioblastoma multiforme.
Journal of Proteomics and Bioinformatics. 2013.
In Press. [Journal]
3)  Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ.
Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.
Transl Oncol. 6: 355-62, 2013.
4)  Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Eur. J. Cancer. 2013.
5)  Rath BH, Fair JM, Jamal M, Camphausen K, Tofilon PJ.
Astrocytes enhance the invasion potential of glioblastoma stem-like cells.
PLoS ONE. 8: e54752, 2013.
6)  Kil WJ, Tofilon PJ, Camphausen K.
Post-radiation increase in VEGF enhances glioma cell motility in vitro.
Radiat Oncol. 7: 25, 2012.
7)  Kahn J, Tofilon PJ, Camphausen K.
Preclinical models in radiation oncology.
Radiat Oncol. 7: 223, 2012.
8)  Gordon IK, Graves C, Kil WJ, Kramp T, Tofilon P, Camphausen K.
Radiosensitization by the novel DNA intercalating agent vosaroxin.
Radiat Oncol. 7: 26, 2012.
9)  Doctrow S, Liesa M, Melov S, Shirihai O, Tofilon P.
Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria.
Curr. Inorganic Chem. 2: 325-334, 2012.
10)  Johnson S, Issac B, Zhao S, Bisht M, Celiku O, Tofilon P, Camphausen K, Shankavaram U.
StRAP: an integrated resource for profiling high-throughput cancer genomic data from stress response studies.
PLoS ONE. 7: e51693, 2012.
11)  Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ.
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Neoplasia. 14: 150-8, 2012.
12)  Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ.
Translation Initiation Factor eIF4E Is a Target for Tumor Cell Radiosensitization.
Cancer Res. 72: 2362-72, 2012.
13)  Shabason JE, Tofilon PJ, Camphausen K.
Grand Rounds at the National Institutes of Health: HDAC Inhibitors as Radiation Modifiers, from Bench to Clinic.
J Cell Mol Med. 15: 2735-44, 2011.
14)  Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K.
Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.
J. Cell. Mol. Med. 16: 545-54, 2011.
15)  Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.
Radiosensitization of glioma cells by modulation of Met signaling with the hepatocyte growth factor neutralizing antibody, AMG102.
J. Cell. Mol. Med. 15: 1999-2006, 2011.
16)  Rosenthal RA, Fish B, Hill RP, Huffman KD, Lazarova Z, Mahmood J, Medhora M, Molthen R, Moulder JE, Sonis ST, Tofilon PJ, Doctrow SR.
Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues.
Anticancer Agents Med. Chem. 11: 359-72, 2011.
17)  Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P.
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.
Neoplasia. 12: 80-6, 2010.
18)  Shabason JE, Tofilon PJ, Camphausen K.
HDAC inhibitors in cancer care.
Oncology. 24: 180-5, 2010.
19)  Jamal M, Rath BH, Williams ES, Camphausen K, Tofilon PJ.
Microenvironmental regulation of glioblastoma radioresponse.
Clin. Cancer Res. 16: 6049-59, 2010.
20)  McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ.
CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.
Clin. Cancer Res. 15: 5145-53, 2009.
21)  Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, Camphausen K.
High throughput evaluation of gamma-H2AX.
Radiat Oncol. 4: 31, 2009.
22)  Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Clin. Cancer Res. 15: 607-12, 2009.
23)  Tofilon PJ, Camphausen K.
Molecular targets for tumor radiosensitization.
Chem. Rev. 109: 2974-88, 2009.
24)  McCord AM, Jamal M, Shankavaram UT, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ.
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
Mol. Cancer Res. 7: 489-97, 2009.
25)  Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clin. Cancer Res. 15: 4292-8, 2009.
26)  Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Mol. Cancer Ther. 8: 1589-95, 2009.
27)  Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Clin. Cancer Res. 14: 931-8, 2008.
28)  Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ.
Postradiation sensitization of the histone deacetylase inhibitor valproic acid.
Clin. Cancer Res. 14: 5410-5, 2008.
29)  Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lü X, Camphausen K, Tofilon PJ.
Radiation-induced gene translation profiles reveal tumor type and cancer-specific components.
Cancer Res. 68: 3819-26, 2008.
30)  Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W, Mehta MP.
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Radiat Oncol. 3: 32, 2008.
31)  Camphausen K, Tofilon PJ.
Inhibition of histone deacetylation: a strategy for tumor radiosensitization.
J. Clin. Oncol. 25: 4051-6, 2007.
32)  Camphausen K, Tofilon PJ.
Inhibition of Hsp90: a multitarget approach to radiosensitization.
Clin. Cancer Res. 13: 4326-30, 2007.
33)  Cerna D, Camphausen K, Tofilon PJ.
Histone deacetylation as a target for radiosensitization.
Curr. Top. Dev. Biol. 73: 173-204, 2006.
34)  Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.
In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Clin. Cancer Res. 12: 2912-8, 2006.
35)  de la Peña L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ.
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Mol. Cancer Ther. 5: 1504-10, 2006.
36)  Dote H, Burgan WE, Camphausen K, Tofilon PJ.
Inhibition of hsp90 compromises the DNA damage response to radiation.
Cancer Res. 66: 9211-20, 2006.
37)  Lü X, de la Peña L, Barker C, Camphausen K, Tofilon PJ.
Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes.
Cancer Res. 66: 1052-61, 2006.
38)  Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.
Clin. Cancer Res. 11: 4571-9, 2005.
39)  Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ.
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Int. J. Cancer. 114: 380-6, 2005.
40)  Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
Cancer Res. 65: 6967-75, 2005.
41)  Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.
Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions.
Proc. Natl. Acad. Sci. U.S.A. 102: 8287-92, 2005.
42)  Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.
Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression.
Cancer Res. 65: 10389-93, 2005.
43)  Camphausen K, Tofilon PJ.
Combining radiation and molecular targeting in cancer therapy.
Cancer Biol. Ther. 3: 247-50, 2004.
44)  Palayoor ST, Burgos MA, Shoaibi A, Tofilon PJ, Coleman CN.
Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Clin. Cancer Res. 10: 4158-64, 2004.
45)  Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ.
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Cancer Res. 64: 316-21, 2004.
46)  Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Clin. Cancer Res. 10: 8077-84, 2004.
47)  Camphausen K, Scott T, Sproull M, Tofilon PJ.
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Clin. Cancer Res. 10: 6066-71, 2004.
48)  Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ.
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Mol. Cancer Ther. 3: 409-16, 2004.
49)  Citrin D, Lee AK, Scott T, Sproull M, Ménard C, Tofilon PJ, Camphausen K.
In vivo tumor imaging in mice with near-infrared labeled endostatin.
Mol. Cancer Ther. 3: 481-8, 2004.
50)  Citrin D, Scott T, Sproull M, Menard C, Tofilon PJ, Camphausen K.
In vivo tumor imaging using a near-infrared-labeled endostatin molecule.
Int. J. Radiat. Oncol. Biol. Phys. 58: 536-41, 2004.
51)  Goley EM, Anderson SJ, Ménard C, Chuang E, Lü X, Tofilon PJ, Camphausen K.
Microarray analysis in clinical oncology: pre-clinical optimization using needle core biopsies from xenograft tumors.
BMC Cancer. 4: 20, 2004.
52)  Lü X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K.
Transcriptional signature of flavopiridol-induced tumor cell death.
Mol. Cancer Ther. 3: 861-72, 2004.
53)  Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ.
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Clin. Cancer Res. 9: 3749-55, 2003.
54)  Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ.
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.
Cancer Res. 63: 7377-83, 2003.
55)  Palayoor ST, Tofilon PJ, Coleman CN.
Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells.
Clin. Cancer Res. 9: 3150-7, 2003.
56)  Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS.
Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001.
Radiat. Res. 159: 812-34, 2003.
57)  Tofilon PJ, Saxman S, Coleman CN.
Molecular targets for radiation therapy: bringing preclinical data into clinical trials.
Clin. Cancer Res. 9: 3518-20, 2003.
58)  Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF.
Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Cancer Res. 62: 1069-76, 2002.
59)  Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ.
Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization.
Cancer Res. 62: 2318-26, 2002.
60)  Russell JS, Tofilon PJ.
Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha).
Mol. Biol. Cell. 13: 3431-40, 2002.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/2/2013.